INTRODUCTION
Reducing mortality in children under five is one of the Millennium Development Goals. 1 Worldwide averages show that four million children die during the first four weeks of life. The main causes are prematurity, asphyxia and sepsis. 2 Intervention through preventive measures has managed to reduce up to 67% of neonatal mortality. 3 In Mexico, 4 2 271 700 deaths were registered in 2003; 20 806 of those deaths occurred during the neonatal period; 49.4% of them were associated to asphyxia.
Detection of critically ill newborn infants offers the possibility of a timely treatment that would have a direct impact on survival and decrease morbidity. Prognostic scales are useful for physicians working in neonatal intensive care units (NICUs). There are scales or scores used at an international level: 5 SNAPPE 6 (Score for Neonatal Acute Physiology Perinatal Extension), CRIB II 7 (Clinical Risk Index for Babies Score) and NEOCOSUR (Neonatal del Cono Sur). 8 They are mostly used in premature infants weighing under 1500 g.
T h i s s t u d y p r o p o s e s t h e development and validation of a score to predict mortality in critically ill newborn infants, without excluding those weighing above 1500 g, based on the inclusion of new prognostic factors.
POPULATION AND METHODS
With the authorization of the local institutional review board (R-2012-6790-89), the study was conducted in Hospital General of Zona 2 A Troncoso, from the Instituto Mexicano del Seguro Social (IMSS), and comprised the following phases: a) Identification of possible predictive outcome measures: From January 2005 to December 2010, a cohort was prospectively defined inclu- Patients who died up to day 7 were considered "cases", and all patients remaining alive up to this timepoint were considered "controls". Six controls were randomly selected per each case (using the Aleator Method software for Excel). c) Assessment of prediction capacity using an independent model: A univariate association of risk variables was conducted, and those found to be significant were subjected to a logistic regression analysis. Nine independent outcome measures were identified (weight, Apgar at five minutes, metabolic acidemia, lactate, alveolar-arterial gradient and ratio, Kirby index and glucose). d) Development of the scale scoring system: Outcome measures resulting from the final model were scored based on the significance of the statistical association reported by other authors (prognosis and meta-analysis articles). [10] [11] [12] [13] [14] [15] [16] [17] [18] Results obtained were compared to those from the first cohort: values reported as normal and within the median were considered as 0 points; values corresponding to the 3rd quartile, 1 point; and the value from the last quartile, 2 points ( Table 1 ). The scale was named Neonatal Mortality Score-9 Mexico (EMN-9 Mex). e) Calculation of the diagnostic accuracy of the scale: individual scores were added up and a ROC curve was developed to determine the best cut-off point and to calculate the area under the curve. Stratification was chosen using the items corresponding to values of 1sensitivity of the following ranges: < 0.5; 0.51-0.75; 0.76-0.94 and ≥ 0.95. f) Prospective validation of the scale: A prospective cohort of newborn infants was designed using data from January 2010 to December 2012. Selection criteria were the same as for the previous cohort. Follow up started at the time newborn infants were admitted at the NICU. Outcome measures included in this scale were taken within the first hour of admission Based on the first phase of the study that included 424 patients admitted in the NICU, with a 5% mortality rate (a= 95% and d= 99%), the odds ratio for a finite population was estimated resulting in a required sample size of 90 newborn infants. A 10% was added for losses and 10 patients were added per outcome measure (90), resulting in a final size of 189 patients. Statistical analysis: for the descriptive statistics central trends (s median) and scatter (interquartile ranges) were used for quantitative outcome measures, and frequencies and percentages were used for qualitative outcome measures. In the first cohort, the risk by odds ratio (OR) was calculated and a logistic regression analysis was performed. For the second cohort, a Cox analysis was carried out and the hazard ratio (HR) was calculated; survival analysis by Kaplan Meier and validity tests (sensitivity, specificity, predictive values, likelihood values and area under the curve) were performed for each of the strata proposed.
The Statistical Package for the Social Sciences (SPSS), version 20 for Windows was used in the statistical package.
RESULTS
First cohort: 424 newborn infants met the eligibility criteria. Twenty-two cases were presented and 132 controls were randomly selected (Figure 1.A) . Differences between cases and controls, as well as risk calculation and adjustment are shown in Table 2 .
Second cohort: During the study period, there was a total of 7 300 deliveries, out of which 306 newborn infants were admitted at the NICU. Finally, 227 patients were included (Figure 1.B) . On average, the early neonatal mortality rate was 8.5 newborn infants per 1000 births; 133 (58%) were classified as very low birth weight for gestational age.
Of the participants, 140 (61%) were male; the median gestational age was 33 weeks (24-39); the median weight was 1100 g (780-2100); and the median height was 43 cm (38-48). Forty-four deaths (19%) were registered.
T h e s c o r e a r e a u n d e r t h e c u r v e w a s 0.92, p <0.0001, for mortality prediction; the confounder-adjusted HR of each stratum is shown in Table 3 . The validity of each stratum is shown in Table 4 . Cumulative survival probability by day 7 was 81%. Figure 2 shows survival by scoring strata.
DISCUSSION
Scales are tools used in medical practice to predict the behavior of a disease, they signal the development of complications or death and are useful for the subsequent evaluation of healthcare programs. 19 The population of the hospital where the study was conducted matches the population characteristics of most cities. Causes of death agree with epidemiology reports from Mexico and the rest of the world. 4 In the first cohort, factors associated with death were identified, and results showed that independent outcome measures in the multicause model were consistent with those found by other authors; some of these were items of already validated scores. 6 However, other outcome measures, such as ventilation and diffusion rates, platelets and hyperglycemia are new compared to the previously mentioned scales.
Perinatal outcome measures did not prove to be useful in our prognostic model; this phenomenon had already been contemplated by the SNAP (Score for Neonatal Acute Physiology) scale in 2001, 20 but ours differs from the NEOCOSUR scale, 8 that does include prenatal variables.
It is worth mentioning that prenatal steroid administration did not prove to be significant on the final model, which differs from reports of the NEOCOSUR group, 8 probably because the population is not held at the study center and the time necessary to artificially induce lung maturation is not enough.
P r e m a t u r i t y i s t h e m a i n c o m o r b i d i t y associated with death and it is represented in our scale by birth weight (due to the likelihood of multi-co-linearity, it was managed this way in our score), given the known relationship between low birth weight and mortality. 21, 22 We consider this finding is timely taking into account that estimating gestational age may not be so B Figure 1 . Selection scheme of the first cohort (A) and the second cohort (B) subjects A reliable to indicate prematurity considering all the chances of variability in the interpretation of rating tools, even among pediatricians. 23 Perinatal asphyxia is one the main causes of death and it is biologically plausible that a low Apgar score and metabolic acidemia are part of the scale. 24 Respiratory disorders, such as respiratory distress syndrome, intrauterine pneumonia or meconium aspiration syndrome are the main comorbidities and their severity affects oxygen diffusion in different degrees. PaO 2 /FiO 2 ratio infers lung damage, whilst p(A-a) O 2 considers the difference between alveolar and capillary oxygen, and A/a shows the same CS: met selection criteria. VLBW: very low birth weight. AWGA: appropriate weight for gestational age. LW/GA: low weight for gestational age. NICU: Neonatal Intensive Care Units. (1,3-11)  2,4 (1,7-3 phenomenon without estimating the FiO 2 effect. 26 The result from both formulas points at a disorder at the alveolar-capillary membrane level. Hypoperfusion states alter lactate and glucose levels 27 and platelet function. 28 Taking into account that most neonatal comorbidities impair tissue oxygen diffusion, it is reasonable that they remain as independent variables and form part of the scale.
None of the previously published scales or scores include hyperglycemia as a mortalityrelated factor. Glucose levels are increased because there is an immaturity in insulin secretion and are associated with conditions that cause death, such as intraventricular hemorrhage, sepsis, necrotizing enterocolitis, among others. 30 The validation cohort of EMN-9 Mex was consistent with the group of patients of the original cohort, in which items constituting this scale arose. All the outcome measures included in the scale kept their significance.
Most mortality scales use β coefficients to determine the predictive weight of their variables. It is difficult to substitute such values in daily practice; for this reason we considered that the development and interpretation of the EMN-9 Mex had to be easy, based on simply adding up points to obtain a score because users are accustomed to similar scales such as the Apgar Score. 31 The SNAP and SNAPPE scales are the most widely used. In their first version, they included a wide range of outcome measures that complicated their implementation, which led to a re-edition in 2001: SNAP-II and SNAPPE II. 8 The latter, unlike our score, was used in 25 429 newborn infants in four hospital facilities, with an area under the curve of 0.91, excluding newborn infants seen at the NICU.
The second version of CRIB 32 was developed following the release of surfactant use. It included newborn infants admitted at intensive care units, but it is designed for patients weighing less than 1500 g, as against our score that took into account newborns of any weight. The CRIB II has been used in different hospitals and it reported an area under the curve of between 0.86 and 0.9. 33 A scale developed using a methodology similar to ours was published in Mexico in 2001. 34 However, the newborn infants used to validate the data were gathered from three referral centers of our country where deliveries are not assisted, so the initial approach might have changed the outcome of subjects included in the study. These conditions affect the external validity of that scale; besides, outcome measures as sepsis and heart failure may vary in their identification depending on who rates them. The interpretation of this scale is based on substituting the β coefficient of each outcome measure in the logistic regression formula, a fact that may delay and complicate its implementation in daily clinical practice. It presents an area under the curve of 0.86 and there are no other publications mentioning to have used it or validated it.
The NEOCOSUR Scale that was developed as a result of a multicenter effort in Latin American countries was validated in a population of over 1800 very low weight newborn infants using six prognostic outcome measures (weight, gestational age, Apgar score at one minute, congenital malformations, prenatal use of steroids and maternal age) with an area under the curve of 0.85, with the advantage of being useful for other outcomes besides mortality, such as bronchopulmonary dysplasia and intraventricular hemorrhage. 35 Compared to other scales or scores, it has a stronger mortality predictive power. 8 Therefore, the EMN-9 Mex is a mortality predictive scale that is easy to implement and interpret, which can be used in newborn infants regardless of their birth weight, and which introduces other outcome measures that have not been used in other scales or scores.
Its weaknesses lie in the fact that the sample size and the target population are restricted to a single center while treatment approach is limited to the institution´s resources. Newborn infants selected were exclusively seen at the Intensive Care Unit and the prognostic power of our score is limited to mortality in the early neonatal stage.
CONCLUSIONS
T h e E M N -9 M e x i s a n o v e l p r o p o s a l validated for newborn infants of all weights, supported in outcome measures covering a Rating of the EMN-9 Mex score p< 0.0001 Log-rank wide spectrum of diseases that lead to neonatal mortality. It would be worth validating it in a larger neonate population in other hospital facilities to specifically check how effective it is for premature, late premature, term and postterm infants. n
